Trial Profile
A Phase 1, Open-label Study to Evaluate the Single Dose Pharmacokinetics of Telotristat Etiprate in Male and Female Subjects With Mild, Moderate and Severe Hepatic Impairment and Matched Subjects With Normal Hepatic Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jan 2019
Price :
$35
*
At a glance
- Drugs Telotristat etiprate (Primary)
- Indications Carcinoid tumour
- Focus Pharmacokinetics
- Sponsors Ipsen
- 31 Aug 2016 Status changed from recruiting to completed.
- 22 Feb 2016 New trial record